Geneva, Switzerland: SkyCell has closed $116m finance package for its technology that improves the pharmaceutical supply chain for air travel. With the fresh capital, SkyCell plans to grow its operations across the US and Asia.
SkyCell makes temperature-controlled containers, using proprietary cold chain technology to monitor cooling, humidity, and shock. The containers also come with a patented insulation system that reflects heat enabling them to self-charge in cold environments such as refrigerated vehicles. This ensures a steady temperature between -80°C to 25°C, depending on the specific model.
SkyCell combines its hardware with software to allow pharma companies to have real-time, end-to-end oversight of the shipments. The software also provides risk assessments throughout the supply chain to help prevent the loss of medications. The company says that its containers transport about $2.5bn worth of pharma goods, including vaccines, as well as cancer treatments and diabetes medication. It also claims that its solution can reduce CO2 emissions by up to 50% thanks to the lightweight, smart containers.
“By digitising the pharma supply chain, transport delays, product wastage, and temperature deviations will be less frequent, and ultimately we will build resilience in the supply chain,” Richard Ettl, SkyCell’s chief executive, said.
